חזרה לתוצאות החיפוש

Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE1, PHASE2

מצבים רפואיים

Head and Neck Squamous Cell Carcinoma (HNSCC) · Pancreatic Adenocarcinoma · Non-small Cell Lung Cancer (NSCLC) · Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC) · Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma · Triple Negative Breast Cancer (TNBC)

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים

  • USC Norris Comprehensive Cancer Center, Los Angeles, California, United States

  • START Midwest, Grand Rapids, Michigan, United States

  • START San Antonio, San Antonio, Texas, United States

  • START Mountain Region, West Valley City, Utah, United States

  • GZA Ziekenhuizen - Campus Sint-Augustinus, Antwerp, Belgium

  • Clinique Universitaires Saint-Luc, Brussels, Belgium

    Contact: Principal Investigator (Rachel Galot)

  • Institute Jules Bordet, Brussels, Belgium

  • CHU Sart Tilman, Liège, Belgium

    Contact: Principal Investigator (Laurence Lousberg)

  • The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

    Contact: Principal Investigator (Jeff Evans)

  • UCL Hospitals NHS Foundation Trust, London, United Kingdom

    Contact: Principal Investigator (Martin Forster)

  • The Christie NHS Foundation Trust, Manchester, United Kingdom

    Contact: Principal Investigator (Donna Graham)

  • Newcastle Upon Tyne NHS Foundation Trust, Newcastle upon Tyne, United Kingdom

    Contact: Principal Investigator (Elizabeth Ruth Plummer)

  • Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom

    Contact: Principal Investigator (Simon Lord)
מובילי המחקר

  • Medical Director

    Study Director

    Exscientia AI Ltd.

צפייה במקור ב־ClinicalTrials.gov(נפתח בחלון חדש)